Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Opicapone versus extra levodopa as first strategy for wearing-off in Parkinson's disease
2020-002754-24Phase 4Active
- Sponsor
- BIAL
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in Parkinson's disease (PD) comparing Opicapone add-on arm with Extra levodopa dose arm (2 arms). Primary endpoint: Change in absolute OFF-time from baseline to end of study. Started Jun 2021; status: active.
02
Drugs
opicaponelevodopa
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2020-002754-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002754-24.